On Friday, Duke Energy Corp (NYSE:DUK)’s shares inclined 1.05% to $76.37.
Duke Energy declared second quarter 2015 adjusted diluted EPS of 95 cents, contrast to $1.11 for the second quarter of 2014. Second quarter 2015 stated EPS was 78 cents, contrast to 86 cents for the same period last year.
Earnings for the second quarter of 2015 were lower than the preceding year quarterly results, primarily due to one-time tax items that did not recur in the current year. Results also were affected by continued weakness in the International business, particularly Brazil, and the timing of O&M expenses at Regulated Utilities.
Year-to-date adjusted diluted EPS through the second quarter of 2015 is in line with the company’s expectations. The company remains on track to achieve its 2015 adjusted diluted earnings guidance range of $4.55 to $4.75 per share.
Duke Energy Corporation, together with its auxiliaries, operates as an energy company in the United States and Latin America. It operates through three segments: Regulated Utilities, International Energy, and Commercial Power. The Regulated Utilities segment generates, transmits, distributes, and sells electricity in the Carolinas, Florida, Ohio, Kentucky, and Indiana; and transports and sells natural gas in southwestern Ohio and northern Kentucky.
Organovo Holdings Inc (NYSEMKT:ONVO)’s shares dropped -3.68% to $2.62.
Organovo Holdings, Inc. (ONVO “), stated its financial results for the first quarter of fiscal 2016 ended June 30, 2015.
Recent Corporate Highlights Comprised of:
- Celebrated the successful launch of its exVive3DTMHuman Liver Tissue, with an declarement of the launch results showing about $2 million in total contract bookings as of June 9, 2015.
- Presented data on the Company’s in vitrothree-dimensional kidney tissue at the 2015 Experimental Biology conference in Boston, Massachusetts, demonstrating fully human kidney proximal tubular tissues were generated that were three-dimensional, and compriseed of multiple tissue-relevant cell types arranged to recapitulate the renal tubular/interstitial interface. This breakthrough result demonstrated a proof of concept that kidney is on the way to becoming another core commercial tissue for Organovo.
- Declared a partnership with L’Oreal USA, wherein L’Oreal’s U.S.-based global Technology Incubator and Organovo will leverage Organovo’s proprietary NovoGen Bioprinting Platform and L’Oreal’s expertise in skin engineering to develop 3D printed skin tissues for product evaluation and other areas of advanced research, marking the first-ever application
Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
At the end of Friday’s trade, Bitauto Hldg Ltd (ADR) (NYSE:BITA)‘s shares surged 0.45% to $29.12.
Bitauto Holdings Limited (BITA), a leading provider of internet content and marketing services for China’s fast-growing automotive industry, recently declared its unaudited financial results for the second quarter 2015 ended June 30, 2015[1].
Second Quarter 2015 Highlights
- Revenue in the second quarter of 2015 was RMB1.01 billion (US$162.2 million), a 92.5% enhance from the corresponding period in 2014.
- Gross profit in the second quarter of 2015 was RMB682.1 million (US$110.0 million), a 62.7% enhance from the corresponding period in 2014.
- Non-GAAP profit in the second quarter of 2015 was RMB122.6 million (US$19.8 million), contrast to a non-GAAP profit of RMB124.2 million (US$20.0 million) in the corresponding period in 2014.
Bitauto Holdings Limited provides Internet content and marketing services for the automotive industry in the People’s Republic of China. The company operates in four segments: bitauto.com Advertising Business, EP Platform Business, taoche.com Business, and Digital Marketing Solutions Business. The bitauto.com Advertising Business segment provides advertising services, counting new automobile pricing and promotional information, specifications, reviews, and consumer feedback to dealers and automakers on its bitauto.com Website.
Mast Therapeutics Inc (NYSEMKT:MSTX), ended its Friday’s trading session with -2.31% loss, and closed at $0.465.
Mast Therapeutics, Inc. (MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, stated financial results for the quarter ended June 30, 2015.
Second Quarter 2015 Operating Results
The Company’s net loss for the second quarter of 2015 was $10.2 million, or $0.06 per share (basic and diluted), contrast to a net loss of $7.2 million, or $0.06 per share (basic and diluted), for the same period in 2014.
Research and development (R&D) expenses for the second quarter of 2015 were $7.7 million, an enhance of $2.9 million, or 61%, contrast to $4.8 million for the same period in 2014. The enhance was due primarily to enhances of $1.9 million in external nonclinical study fees and expenses, $0.8 million in external clinical study fees and expenses and $0.2 million in personnel expenses.
The $1.9 million enhance in external nonclinical study fees and expenses was due primarily to a $1.7 million enhance in research-related manufacturing costs for vepoloxamer and a $0.2 million enhance in research-related manufacturing costs for AIR001. The $0.8 million enhance in external clinical study fees and expenses was due primarily to an enhance of $1.2 million in EPIC study costs, offset by a decrease of $0.4 million in AIR001 study costs.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases. The company’s lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
